International Stem Cell Corp., a California-based biotech company developing novel stem cell-based therapies and biomedical products, this morning said it will make an oral presentation on the comprehensive results of its preclinical development of human parthenogenetic neural stem cells (hPNSCs) for the treatment of Parkinson’s Disease at the upcoming Neuroscience 2015 in Chicago.
The session, entitled, “Therapeutics of Parkinson’s Disease: Preclinical Studies,” will take place October 20 from 8 a.m.-10:15 a.m. ET.
“The comprehensive data collected from our extensive GLP studies serve as proof of safety and efficacy for our planned clinical trial for the treatment of Parkinson’s Disease in Australia. We look forward to providing an update on the status of our regulatory submission to the Australian government in the near future,” Russell A. Kern, Ph.D. chief scientific officer of ISCO, stated in the news release.
ISCO’s Parkinson’s disease program uses human parthenogenetic neural stem cells (hPNSC), which are a novel therapeutic cellular product derived from ISCO’s proprietary human pluripotent stem cells. hPNSC are self-renewing multipotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to differentiate into dopaminergic neurons and express neurotrophic factors to protect the nigrostriatal system offers a new opportunity for the treatment of Parkinson’s disease.
ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).
For more information visit www.internationalstemcell.com
